NEW YORK--(BUSINESS WIRE)--
The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) stock prior to April 30, 2018.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of SteadyMed to United Therapeutics Corporation (NASDAQGS: UTHR). Under the terms of the transaction, SteadyMed shareholders will receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device combination product. To learn more about the action and your rights, go to:
http://www.zlk.com/mna/steadymed-ltd
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The investigation concerns whether the Board of SteadyMed breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether United Therapeutics Corporation is underpaying for SteadyMed shares, thus unlawfully harming SteadyMed shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180502006222/en/
